Digital Public Defence Apr. 26, 2021 12:15 Maxi-Lu Böschen

Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B (2025)
Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes
Commun Biol, 8 (1), 992
DOI 10.1038/s42003-025-08413-0, PubMed 40610675

Hurley JH, Coyne AN, Miączyńska M, Stenmark H (2025)
The expanding repertoire of ESCRT functions in cell biology and disease
Nature, 642 (8069), 877-888
DOI 10.1038/s41586-025-08950-y, PubMed 40562928

Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA (2025)
Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis
J Transl Med, 23 (1), 672
DOI 10.1186/s12967-025-06644-7, PubMed 40528241

Gudiño V, Bartolomé-Casado R, Salas A (2025)
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications
Gut, 74 (8), 1335-1345
DOI 10.1136/gutjnl-2024-334165, PubMed 39904604

Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B (2025)
Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes
Commun Biol, 8 (1), 992
DOI 10.1038/s42003-025-08413-0, PubMed 40610675

Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C (2025)
Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
Pharmacoepidemiol Drug Saf, 34 (7), e70181
DOI 10.1002/pds.70181, PubMed 40552731